Acute Lower Extremity Arterial Thrombosis Associated with Osimertinib-Induced Erythrocytosis

Shota Kodaira; Jun Ehara; Shigemasa Takamizawa; Shin Ogita; Yasuhiro Norisue; Tatsuya Nakama; Eiji Hiraoka

doi:10.12659/AJCR.932252

07 September 2021 : Case report Japan

Acute Lower Extremity Arterial Thrombosis Associated with Osimertinib-Induced Erythrocytosis

Unusual or unexpected effect of treatment, Adverse events of drug therapy

Shota Kodaira^1AEF, Jun Ehara^12AEF*, Shigemasa Takamizawa

^1AEF, Shin Ogita^3EF, Yasuhiro Norisue^2E, Tatsuya Nakama^4E, Eiji Hiraoka^1AEF

DOI: 10.12659/AJCR.932252

Am J Case Rep 2021; 22:e932252

Authors information Article notes Copyright and License information

Background Case Report Discussion Conclusions References:

View HTML version

Figure 1. The trend of hemoglobin (Hb) level. The trend of Hb level from the initiation of osimertinib therapy is shown. The arrow indicates the timepoint at which acute arterial thrombosis developed and osimertinib was discontinued.

Back to the Article

Acute Lower Extremity Arterial Thrombosis Associated with Osimertinib-Induced Erythrocytosis

Your Privacy